-
1
المؤلفون: Mario Mandalà, Juliette Murris, Paola Queirolo, Ana Arance, Caroline Dutriaux, Helen Gogas, Gabriella Liszkay, Ralf Gutzmer, Claus Garbe, Keith T. Flaherty, Abir Tadmouri Sellier, Naoya Yamazaki, Jeanne Suissa, Ivana Krajsová, Vanna Chiarion Sileni, Caroline Robert, Reinhard Dummer, Groot Jan de Willem, Paolo A. Ascierto, Ashwin Gollerkeri, Carmen Loquai, Dirk Schadendorf
المساهمون: University of Zurich
مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business
الوصف: In COLUMBUS, treatment with encorafenib plus binimetinib in patients with advanced BRAF-mutant melanoma showed improved progression-free and overall survival with favourable tolerability compared to vemurafenib treatment. Here, results on health-related quality of life (HRQoL) are presented.COLUMBUS was a two-part, open-label, randomised, phase III study in patients with BRAF-mutant melanoma. In PART-I, 577 patients were randomised (1:1:1) to encorafenib plus binimetinib, encorafenib or vemurafenib. The primary objective was to assess progression-free survival. As a secondary objective, HRQoL was assessed by the EQ-5D, the EORTC QLQ-C30 and the FACT-M questionnaires. Furthermore, time to definitive 10% deterioration was estimated with a Kaplan-Meier analysis and differences in mean scores between groups were calculated with a mixed-effect model for repeated measures. Hospitalisation rate and the impact of hospitalisation on HRQoL were also assessed.Patients receiving the combination treatment showed improvement of their FACT-M and EORTC QLQ-C30 global health status scores, compared to those receiving vemurafenib (post-baseline score differences: 3.03 [p 0.0001] for FACT M and 5.28 [p = 0.0042] for EORTC QLQ-C30), indicative of a meaningful change in patient's status. Furthermore, a delay in the deterioration of QoL was observed in non-hospitalised patients compared to hospitalised patients (hazard ratio [95% CI]: 1.16 [0.80; 1.68] for EORTC QLQ-C30 and 1.27 [0.81; 1.99] for FACT-M) and a risk reduction of 10% deterioration, favoured the combination in both groups.The improved efficacy of encorafenib plus binimetinib compared to vemurafenib, translates into a positive impact on the perceived health status as assessed by the HRQoL questionnaires. The study is registered with ClinicalTrials.gov, number NCT01909453 and EudraCT number 2013-001176-38.
وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/ -
2دورية أكاديمية
المؤلفون: Gogas, Helen, Dummer, Reinhard, Ascierto, Paolo A, Arance, Ana, Mandala', Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsová, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, Yamazaki, Naoya, Loquai, Carmen, Queirolo, Paola, Jan de Willem, Groot, Sellier, Abir Tadmouri, Suissa, Jeanne, Murris, Juliette, Gollerkeri, Ashwin, Robert, Caroline, Flaherty, Keith T
المساهمون: Gogas, Helen, Dummer, Reinhard, Ascierto, Paolo A, Arance, Ana, Mandala', Mario, Liszkay, Gabriella, Garbe, Clau, Schadendorf, Dirk, Krajsová, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, Yamazaki, Naoya, Loquai, Carmen, Queirolo, Paola, Jan de Willem, Groot, Sellier, Abir Tadmouri, Suissa, Jeanne, Murris, Juliette, Gollerkeri, Ashwin, Robert, Caroline, Flaherty, Keith T
مصطلحات موضوعية: BRAF(V600E−K) mutant Melanoma, BRAF/MEK inhibitors Combination, Encorafenib plus binimetinib, Health-related quality of life, Hospitalisation rate
الوصف: In COLUMBUS, treatment with encorafenib plus binimetinib in patients with advanced BRAF-mutant melanomashowed improved progression-free and overall survival with favourable tolerability compared to vemurafenib treatment. Here, results on health-related quality of life (HRQoL) are presented.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34091420; info:eu-repo/semantics/altIdentifier/wos/WOS:000678059500012; volume:152; firstpage:116-128; lastpage:128; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11391/1493907Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85107650414
